Starting from pathogenesis characterization and epidemiological analysis of RET fusions in advanced NSCLC, we will subsequently compare the clinical outcome achieved after MKIs and/or RET-selective TKIs’ administration, using both retrospective and prospective trials’ results. This evidence concerns the gene RET and non-small cell lung carcinoma.